Flying Blind on the Origin of the Pandemic

I was always curious. An early elementary school memory is my mother returning from a parent teacher conference to report that my teacher thought I had “an inquiring mind.” Curiosity is what led me to...

Why Astrazeneca and J&J’s vaccines, in use the world over, are still on hold...

The World Health Organization greenlighted emergency use of AstraZeneca and Oxford's covid-19 vaccine this month, following in the steps of the United Kingdom, the European Union and others, who are already injecting it as...

Immune Cell Signaling to the Brain Regulates Anxiety-Like Behaviors

Researchers at Washington University School of Medicine in St. Louis have made the surprising finding that specific cells of the immune system can affect both mind and body. Their research in mice demonstrated that...

Genomic Basis of Bat Superpowers Could Provide New Insights into Coronavirus Resistance

Scientists have for the first time sequenced the genetic material that codes for bats’ unique adaptations and superpowers, such as the ability to fly, to use sound to move effortlessly in complete darkness, to...

Quartet of COVID-19 Vaccine Candidates Head Toward the Homestretch

William A. Haseltine, PhD Viewed as a horse race, none of the four COVID-19 vaccine candidates whose developers released early clinical data this month fully broke away from the pack galloping toward regulatory approval. However, a...

Epigenetic Clock More Accurately Aligns Dog Age to Human Years

To calculate your dog’s age in “human years” based on epigenetics, find the dog’s age along the bottom axis and trace your finger straight up until you reach the red curve. Then trace your...

U.K. Starts Oxford Coronavirus Vaccine Trial as Germany Green-Lights BioNTech and Pfizer

The first human trials of a coronavirus vaccine developed by researchers at the University of Oxford will start today in the U.K. Making the announcement at a recent press briefing, U.K. government Health Secretary...

GSK Invests $250M in Vir as Companies Partner on COVID-19 Candidates

George Scangos, CEO of Vir Biotechnology GlaxoSmithKline (GSK) will invest $250 million in Vir Biotechnology as part of an R&D collaboration designed to advance COVID-19 candidates into Phase II clinical trials later this year, the...

Cytiva Picks Up Where GE Leaves Off after $21B Deal

Cytiva will also look to grow through expanded activity in cell and gene therapies—and additional work with customers working toward COVID-19 drugs, vaccines, and tests . . . The post Cytiva Picks Up Where GE...

Moderna’s SARS-CoV-2 Vaccine’s Fast Track to Clinical Trials

The holy grail of the current pandemic—a vaccine for COVID-19—will not be available next month. It may not even be ready by next year. Regardless, the strides being made are happening at unprecedented speed....